Market Cap | 22.47M | P/E | - | EPS this Y | 25.80% | Ern Qtrly Grth | - |
Income | -8.54M | Forward P/E | -1.03 | EPS next Y | -130.40% | 50D Avg Chg | -6.00% |
Sales | 57k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
Dividend | N/A | Price/Book | 2.23 | EPS next 5Y | - | 52W High Chg | -60.00% |
Recommedations | 2.00 | Quick Ratio | 7.04 | Shares Outstanding | 36.32M | 52W Low Chg | 65.00% |
Insider Own | 19.16% | ROA | -52.34% | Shares Float | 25.54M | Beta | 1.58 |
Inst Own | 14.57% | ROE | -101.84% | Shares Shorted/Prior | 34.06K/27.75K | Price | 0.78 |
Gross Margin | 15.79% | Profit Margin | - | Avg. Volume | 27,970 | Target Price | - |
Oper. Margin | -3,798.25% | Earnings Date | Nov 12 | Volume | 7,416 | Change | -0.01% |
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
HC Wainwright & Co. | Buy | Sep 27, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
HC Wainwright & Co. | Buy | Jun 5, 24 |
HC Wainwright & Co. | Buy | May 14, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
HC Wainwright & Co. | Buy | Apr 2, 24 |
HC Wainwright & Co. | Buy | Dec 11, 23 |
HC Wainwright & Co. | Buy | Sep 13, 23 |
HC Wainwright & Co. | Buy | Sep 11, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Taitel Haya | Director Director | Jan 12 | Buy | 0.99 | 9,500 | 9,405 | 35,115 | 01/16/24 |
Taitel Haya | Director Director | Jan 10 | Buy | 0.77 | 7,615 | 5,864 | 25,615 | 01/11/24 |
LIEBERMAN GERALD M | Director Director | Dec 22 | Buy | 0.71 | 23,952 | 17,006 | 226,961 | 12/27/23 |
Toledano Miranda Jayne | Chief Executive Offi.. Chief Executive Officer | Dec 22 | Buy | 0.71 | 23,952 | 17,006 | 110,752 | 12/27/23 |
Taitel Haya | Director Director | Aug 22 | Buy | 0.6231 | 18,000 | 11,216 | 18,000 | 08/24/23 |
LIEBERMAN GERALD M | Director Director | Aug 21 | Buy | 0.5892 | 20,000 | 11,784 | 214,209 | 08/23/23 |
Ellis Sean | Director Director | Jul 21 | Buy | 1.638 | 14,900 | 24,406 | 32,100 | 07/25/22 |
LIEBERMAN GERALD M | Director Director | Jul 21 | Buy | 1.683 | 19,491 | 32,803 | 160,209 | 07/25/22 |
OSTROV GERALD M | Director Director | Jan 13 | Buy | 2.7378 | 10,000 | 27,378 | 10,000 | 01/25/22 |
Ratan Ramesh | U.S.based CFO U.S.based CFO | Jan 19 | Buy | 2.4364 | 10,000 | 24,364 | 10,000 | 01/24/22 |
JAMAS SPIROS | Chief Executive Offi.. Chief Executive Officer | Jan 18 | Buy | 2.85 | 10,000 | 28,500 | 10,000 | 01/24/22 |
Schwartz Phillip | President of R&D President of R&D | Jan 20 | Buy | 2.525 | 10,000 | 25,250 | 607,410 | 01/24/22 |
LIEBERMAN GERALD M | Director Director | Jan 18 | Buy | 2.8 | 2,800 | 7,840 | 2,200 | 01/24/22 |